Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cynata Therapeutics Ltd V.CYP


Primary Symbol: CYYNF

Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and regenerative medicine company. The Company is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells and a precursor cell, mesenchymoangioblast (MCA) to manufacture cell therapy products, including mesenchymal stem cells, on a commercial scale. Its lead product candidate, CYP-001, is under Phase I trial and developed for the treatment of steroid-resistant acute graft-versus-host disease (GvHD). Clinical trials of Cymerus products in osteoarthritis, which is under Phase III trial, and diabetic foot ulcers (DFU) are ongoing. In addition, the Company has demonstrated the utility of its Cymerus technology in preclinical models of various diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome and other.


OTCPK:CYYNF - Post by User

Bullboard Posts
Post by GarryJan1on May 06, 2019 9:46pm
84 Views
Post# 29717539

Cypress has to spend $200,000 before

Cypress has to spend $200,000 before November 8th as part of there Option agreement with Dajin.

Under the terms of the Agreement, Cypress will have the exclusive right and option to acquire a 50% undivided interest in Dajin’s unpatented placer mining claims and application for water rights in Alkali Spring valley, Esmeralda County, Nevada.  Subject to TSX Venture Exchange acceptance, Cypress will allot to Dajin 150,000 common shares of Cypress and pay Dajin USD$50,000.  Cypress will have a two-year period to complete its earn-in by issuing an additional 150,000 common shares of Cypress and performing USD$200,000 in exploration expenditures within the first year and USD$250,000 in exploration expenditures during the second year.  Upon successful completion of the two year earn-in period a joint venture (JV) will be created.

At Alkali Spring valley, Dajin holds 145 unpatented placer mining claims to explore for lithium brines and has applied to the State of Nevada for 1,000 acre-feet of water rights.  Dajin and Cypress will work jointly to explore the property for lithium brines and lithium-bearing sediments, and will work to perfect the associated water rights applications. Cypress and Dajin will share proportionally in property development once the terms of the earn-in agreement have been met and the joint venture is created.

Bullboard Posts